<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: The objective of this study was to examine the associations between the severity of <z:hpo ids='HP_0001397'>hepatic steatosis</z:hpo> and <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, including circulating <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> B100 (apoB) concentrations and <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> particle size and numbers </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: Computed tomography imaging was used to assess hepatic fat content and adipose tissue distribution in 67 men and women with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, withdrawn from <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> medications preceding the study </plain></SENT>
<SENT sid="2" pm="."><plain>Fasting serum <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> number and size was determined by nuclear magnetic resonance </plain></SENT>
<SENT sid="3" pm="."><plain>Insulin sensitivity was measured with a <z:chebi fb="105" ids="17234">glucose</z:chebi> clamp and a [6,6-(2)H(2)]<z:chebi fb="105" ids="17234">glucose</z:chebi> isotope infusion </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Two-thirds of the cohort had <z:hpo ids='HP_0001397'>fatty liver</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0001397'>Hepatic steatosis</z:hpo> correlated with serum <z:chebi fb="4" ids="17855">triglycerides</z:chebi> (r = 0.40, P &lt; 0.01) and lower <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> (r = -0.31, P &lt; 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>ApoB and <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> did not, being virtually identical in those with or without <z:hpo ids='HP_0001397'>steatosis</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>The association between serum <z:chebi fb="4" ids="17855">triglycerides</z:chebi> and <z:hpo ids='HP_0001397'>hepatic steatosis</z:hpo> was largely accounted for by greater <z:chebi fb="0" ids="17855">triglyceride</z:chebi> enrichment in <z:chebi fb="1" ids="39027">VLDL</z:chebi> particles, which were larger </plain></SENT>
<SENT sid="8" pm="."><plain>Severe <z:hpo ids='HP_0001397'>steatosis</z:hpo> was also associated with 70% higher small, dense <z:chebi fb="15" ids="39026">LDL</z:chebi> concentrations </plain></SENT>
<SENT sid="9" pm="."><plain>Visceral <z:hpo ids='HP_0001513'>obesity</z:hpo> did not fully explain these associations, and <z:hpo ids='HP_0001397'>hepatic steatosis</z:hpo> was better correlated with <z:chebi fb="4" ids="17855">triglycerides</z:chebi> than with <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> or hepatic <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> (P &gt; 0.05) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: The presence of <z:hpo ids='HP_0001397'>hepatic steatosis</z:hpo> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> does not appear to affect apoB levels, but potentially increases atherogenesis by increasing <z:chebi fb="4" ids="17855">triglycerides</z:chebi>, reducing <z:chebi fb="17" ids="39025">HDL</z:chebi> levels, and increasing small, dense <z:chebi fb="15" ids="39026">LDL</z:chebi> </plain></SENT>
</text></document>